Recurrent Headaches Without Red Flags: Evaluation and Management
For recurrent headaches without red-flag features, neuroimaging is not indicated; instead, establish the diagnosis using ICHD-3 criteria with a headache diary, then initiate appropriate acute and preventive therapy based on headache type. 1
Initial Diagnostic Approach
Do not order neuroimaging for typical recurrent headaches with a normal neurological examination—the yield is extremely low (brain tumors 0.8%, vascular malformations 0.2%) and adds unnecessary cost and radiation exposure. 1, 2 Neuroimaging is only warranted when red-flag features are present in the history or physical examination. 1, 3
Essential History Elements
Implement a headache diary immediately—patients consistently underestimate headache frequency, and diary documentation is essential for accurate diagnosis and treatment monitoring. 4, 5
Apply ICHD-3 diagnostic criteria systematically to distinguish between primary headache types. 1
Screen specifically for medication overuse—directly ask about all over-the-counter analgesics, NSAIDs, triptans, and any medications obtained from others, as this is frequently missed. 1, 4, 5
Differential Diagnosis Framework
Migraine without aura requires ≥5 lifetime attacks lasting 4-72 hours (in adults), ≥2 pain characteristics (unilateral, pulsating, moderate-to-severe intensity, aggravation by routine activity), and ≥1 associated symptom (nausea/vomiting or both photophobia and phonophobia). 4, 6
Tension-type headache presents with bilateral pressing/tightening pain of mild-to-moderate intensity, not aggravated by routine physical activity, and lacking the associated symptoms of migraine (no nausea/vomiting and no combination of photophobia plus phonophobia). 1, 4
Medication-overuse headache (MOH) should be suspected when non-opioid analgesics are used ≥15 days/month or triptans/combination analgesics ≥10 days/month for >3 months. 4, 7, 5 This is a critical diagnosis because preventive therapy will fail until medication overuse is eliminated. 7
Acute Treatment Strategy
For Mild-to-Moderate Attacks
Ibuprofen 400-800 mg every 6 hours is first-line therapy. 4, 6
Naproxen sodium 275-550 mg every 2-6 hours or aspirin 650-1,000 mg every 4-6 hours are alternative NSAIDs. 1, 4
Aspirin-acetaminophen-caffeine combination products are effective for mild-to-moderate migraine. 1, 6
For Moderate-to-Severe Attacks or NSAID Failure
Triptans (sumatriptan, rizatriptan, zolmitriptan, naratriptan) are migraine-specific agents that eliminate pain in 20-30% of patients by 2 hours. 1, 4, 6 However, avoid triptans in patients with cardiovascular disease due to vasoconstrictive properties. 6
Gepants (rimegepant, ubrogepant) are CGRP receptor antagonists that eliminate headache in 20% of patients at 2 hours and are safe in patients with cardiovascular risk factors. 6
Lasmiditan (5-HT1F agonist) is another migraine-specific option safe for patients with cardiovascular disease. 6
Adjunctive Therapy
Ondansetron 8 mg sublingual/oral every 4-6 hours for associated nausea/vomiting. 4
Metoclopramide or prochlorperazine are alternative antiemetics. 1, 4
Critical Medication Limits
Limit all acute medications to ≤10 days per month (or ≤2 days per week) to prevent medication-overuse headache. 4, 7, 5 This is non-negotiable—exceeding this threshold will transform episodic headaches into chronic daily headaches. 5
Never use opioids (meperidine, butorphanol) for recurrent headaches—they cause dependency, rebound headaches, and eventual loss of efficacy. 1, 4
Preventive Therapy Indications
Initiate preventive therapy when any of the following criteria are met: 4, 8, 5
- ≥2 headache days per month with significant disability
- Impaired quality of life despite optimized acute treatment
- Chronic migraine (≥15 headache days/month for >3 months with ≥8 migraine days)
- Rescue medication use >2 times per week
- Contraindications to or failure of acute treatments
First-Line Preventive Agents
Propranolol (beta-blocker) is first-line for migraine prevention. 4
Amitriptyline is first-line for chronic tension-type headache. 4
Topiramate is an alternative first-line preventive agent. 7, 6
CGRP monoclonal antibodies reduce migraine frequency by 1-3 days per month relative to placebo. 6
Management of Medication-Overuse Headache
If MOH is present, preventive therapy will not work until medication overuse is eliminated. 7 The approach depends on the overused medication:
For NSAIDs, triptans, or simple analgesics: abrupt withdrawal is usually safe and can be managed outpatient. 5
For opioids, barbiturates, or benzodiazepines: slow tapering is required, possibly with inpatient treatment to prevent acute withdrawal. 5
Simultaneously initiate preventive therapy (topiramate or propranolol) while addressing medication overuse. 7
Lifestyle Modifications
Implement these interventions concurrently with pharmacotherapy: 7
- Limit caffeine intake
- Regular meals and adequate hydration
- Sleep hygiene optimization
- Regular aerobic exercise
- Stress management techniques
Follow-Up and Monitoring
Re-evaluate in 2-3 months to assess headache frequency reduction, response to acute treatment, medication overuse patterns, and preventive medication tolerability. 7
Continue headache diary documentation throughout treatment to objectively track progress. 4, 5
Referral Criteria
Urgent neurology referral (within 48 hours) is indicated for: 4, 8
- Any red-flag features developing during follow-up
- Inability to self-care despite assistance
- Suspected spontaneous intracranial hypotension
Routine neurology referral (2-4 weeks) is appropriate when: 4, 7
- Diagnosis remains uncertain after diary review
- Poor response to two first-line preventive medications
- Attacks become more frequent or severe despite treatment
- Atypical features persist despite negative workup
Additional Considerations for Specific Populations
For patients >50 years with new-onset headache pattern: consider ESR and CRP to exclude giant cell arteritis, even without other red flags. 7, 2 Temporal arteritis can present with nonspecific headache, and ESR can be normal in 10-36% of cases. 2
Repeat neuroimaging, EEG, or additional blood work is not routinely helpful once secondary causes have been excluded with initial evaluation. 7